Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Study suggests current lung cancer screening guidelines may be inadequate for HIV-positive people.
People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.
Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.
The trial is testing an experimental drug that targets one of the malignant immune cells that are a hallmark of the disease.
HIV-positive women had shorter overall survival than HIV-negative women with breast cancer in a study in Botswana.
Timothy Brown may have company after a man’s virus went into remission following an HIV-resistant stem cell transplant to treat his cancer.
Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.
Failure to catch cancer early means many younger patients are diagnosed with advanced disease.
A high-fiber diet may help checkpoint medications work better—but probiotic supplements could interfere with response.
Conservative management is now the most common choice for men with low-risk prostate cancer.
However, successful treatment of HIV, including having a high CD4 count, may buffer against such a risk.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
Darolutamide delays metastasis and reduces the risk of death in men with high-risk prostate cancer.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
These men lived for a median of 30 months compared to 26 months for white men.
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.